What is a suitable medication therapy for anxiety in a 90-year-old male?

Medication Therapy for Anxiety in a 90-Year-Old Male

Primary Recommendation

Start with sertraline or escitalopram as first-line pharmacotherapy, beginning at low doses (sertraline 25 mg daily or escitalopram 5 mg daily) and titrating gradually based on tolerability and response. 1, 2, 3

---

Preferred First-Line Agents

SSRIs: Sertraline and Escitalopram

• Sertraline and escitalopram are the preferred options for older adults due to their favorable safety profiles and minimal drug-drug interaction potential 1, 4
• Escitalopram has the least effect on CYP450 isoenzymes compared to other SSRIs, resulting in lower propensity for drug interactions—a critical consideration in elderly patients often taking multiple medications 5
• Both agents have demonstrated efficacy in generalized anxiety disorder and other anxiety disorders with effect sizes of SMD -0.55 to -0.67 compared to placebo 4
• Sertraline is FDA-approved for multiple anxiety disorders including panic disorder, social anxiety disorder, and PTSD 3
• Escitalopram is FDA-approved for generalized anxiety disorder, demonstrating statistically significant improvement on the Hamilton Anxiety Scale in adults ages 18-80 2

Dosing Strategy for Elderly Patients

• Start low and go slow: Begin SSRIs at lower doses than in younger adults and titrate gradually 1
• For sertraline: Start at 25 mg daily (half the standard adult starting dose)
• For escitalopram: Start at 5 mg daily (half the standard adult starting dose)
• Increase doses at 1-2 week intervals for shorter half-life SSRIs (sertraline) to 3-4 week intervals for longer half-life SSRIs, monitoring for tolerability 5
• Target therapeutic range: sertraline 50-150 mg daily, escitalopram 10-20 mg daily, adjusting based on response and adverse effects 2, 3

---

Medications to Avoid or Use with Extreme Caution

Avoid These SSRIs in Elderly

• Paroxetine and fluoxetine should generally be avoided in older adults due to higher rates of adverse effects 1
• Paroxetine has significant anticholinergic properties and is associated with increased risk of suicidal thinking compared to other SSRIs 5
• Fluoxetine has a very long half-life and extensive CYP2D6 interactions, making it problematic in elderly patients 5

Benzodiazepines: Use Only as Short-Term Bridge

• Benzodiazepines are not recommended for routine use in anxiety disorders, particularly in the elderly 6, 4
• If lorazepam must be used temporarily (e.g., as adjunctive therapy during the first 2-4 weeks while waiting for SSRI onset), reduce the dose to 0.25-0.5 mg in elderly patients with a maximum of 2 mg in 24 hours 1, 7
• Lorazepam carries significant risks in elderly including sedation, falls, cognitive impairment, and risk of dependence 7
• Short-term adjunctive use (first few weeks only) may be considered in selected patients while awaiting antidepressant onset of action 8

---

Alternative Options if SSRIs Fail or Are Not Tolerated

SNRIs as Second-Line

• Venlafaxine extended-release or duloxetine are appropriate alternatives if SSRIs are ineffective or not tolerated 1, 4
• SNRIs demonstrate similar efficacy to SSRIs with effect sizes of SMD -0.55 for generalized anxiety disorder 4
• Start at low doses and titrate gradually, similar to SSRI approach 1

---

Treatment Monitoring and Duration

Assessment Timeline

• Assess treatment response at 4 weeks and 8 weeks using standardized validated instruments 1
• Monitor for symptom relief, side effects, adverse events, and patient satisfaction at each visit 1
• Initial adverse effects of SSRIs can include anxiety or agitation, which typically resolve within 1-2 weeks 5

Treatment Adjustment Strategy

• If symptoms are stable or worsening after 8 weeks despite good adherence, adjust the regimen by: 1
  • Switching to a different SSRI or SNRI
  • Adding cognitive behavioral therapy if not already implemented
  • Reassessing for medical causes of anxiety (thyroid disease, cardiac arrhythmias, medication side effects)

Duration of Treatment

• For a first episode of anxiety, continue treatment for at least 4-12 months after symptom remission 1
• For recurrent anxiety, longer-term or indefinite treatment may be beneficial 1
• After remission, medications should be continued for 6-12 months before considering gradual taper 6

---

Critical Considerations for This Population

Non-Pharmacological Approaches

• Address non-pharmacological factors including exploring the patient's specific concerns and anxieties, ensuring effective communication and orientation, and treating reversible causes of anxiety (pain, delirium, medication effects) 1
• Cognitive behavioral therapy has the highest level of evidence for anxiety disorders across all age groups and should be offered alongside or instead of medication when available 1, 4

Medical Workup

• Rule out medical causes: hyperthyroidism, cardiac arrhythmias, hypoglycemia, medication effects (corticosteroids, bronchodilators, stimulants), caffeine excess, alcohol withdrawal 8
• Screen for comorbid depression, as panic disorder and anxiety have high comorbidity with depressive disorders in elderly patients 8
• When both depression and anxiety symptoms are present, prioritize treatment of depressive symptoms or use a unified protocol 1

Drug Interactions and Safety

• Review all current medications for potential interactions, particularly with CYP450 substrates 5
• Monitor for QT prolongation if using citalopram (avoid doses >20 mg daily in patients >60 years old) 5
• Assess fall risk and implement fall prevention strategies, as anxiety medications can increase fall risk in elderly 1

---

Common Pitfalls to Avoid

• Do not start at standard adult doses—elderly patients require lower starting doses and slower titration 1
• Do not use benzodiazepines as monotherapy or for extended periods due to dependence risk, cognitive impairment, and falls 7, 6
• Do not discontinue SSRIs abruptly—taper gradually to avoid discontinuation syndrome (dizziness, paresthesias, anxiety, irritability) 5
• Do not assume anxiety is purely psychiatric—always evaluate for underlying medical causes in elderly patients presenting with new-onset anxiety 8
• Do not overlook cognitive behavioral therapy—it has equivalent or superior efficacy to pharmacotherapy and should be offered when available 1, 4